Prasinezumab is a monoclonal antibody that selectively binds aggregated alpha-synuclein. Prasinezumab is under investigation as a disease-modifying therapeutic candidate for early-stage Parkinsons disease, where it is being evaluated for its ability to interfere with pathogenic alpha-synuclein aggregation and progression of neurodegeneration.
Purity:
0.975
CAS Number:
[1960462-19-4]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
